Comparison of 4 Influenza Vaccines in Seniors (PCIRNRT09)

Controlled Comparison in Canadian Seniors of Seasonal Influenza Vaccines for 2011-2012

Based on information from several years of looking at Influenza vaccination doctors know that:

• Older adults suffer the worst illness and most deaths caused by Influenza illness of all age groups.
• Older adults do not seem to get as good a level of protection as younger adults after getting the usual seasonal Influenza vaccine.

Because of this information doctors wonder if one of the new seasonal Influenza vaccines is more effective or more acceptable.

This study has been designed to answer some of these questions. On this study doctors will compare 2 new vaccines against the usual seasonal influenza vaccine for protectiveness using several different testing methods (including the usual tests) and for acceptability.

Study Overview

• Status: Completed
• Conditions: Influenza Vaccine
• Intervention / Treatment: Biological: Agriflu; Biological: Fluad; Biological: Intanza; Biological: Vaxigrip

Detailed Description

This study is prospective, multicenter, randomized, evaluator-blinded, controlled, parallel group study of 3 licensed seasonal influenza vaccine products conducted in seniors, with a 4th vaccine included in a substudy of cellular immune responses.

Ambulatory adults 65+ years of age, in good health or with stable health conditions, given TIV within the past 2 years, will be recruited in multiple Canadian centres. Subjects can be dwelling in the community or in centers providing minimal assisted living support. A total of 930 subjects will be enrolled.

Subjects will be centrally (electronically) randomized to receive either TIV, IDV or AIV on Day 0. Three blood samples will be collected (1 pre and 2 post vaccination) to measure HAI antibody responses to each virus strain (H1N1, H3N2 and B) in each vaccine, using standardized assays. Randomly selected subsets of sera from each study group will also be tested for neutralizing antibody and for cross-protection against drift variants of H3N2, H1N1 and B viruses. In a subset of subjects in Vancouver, randomization assignments will include TIV2 and extra blood samples will be obtained 0, 21 and 72 days post vaccination for CMI testing. Safety assessments will be conducted on Day 7, Day 21 and Day 180 following vaccination. Acceptability of each product, reflecting the frequency, severity and tolerability of adverse effects, will be assessed.

• Study Type: Interventional
• Enrollment (Actual): 953
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
      • University of British Columbia, VITALiTY Research Center
  • Manitoba
    • Winnipeg, Manitoba, Canada
      • University of Manitoba, Department of Medicine
  • Nova Scotia
    • Halifax, Nova Scotia, Canada
      • Canadian Centre for Vaccinology Dalhousie University
  • Ontario
    • Hamilton, Ontario, Canada
      • McMaster University
    • Ottawa, Ontario, Canada
      • The Ottawa Hospital Research Institute, University of Ottawa
    • Toronto, Ontario, Canada
      • University of Toronto, Mt Sinai Hospital
  • Quebec
    • Montreal, Quebec, Canada
      • McGill University Health Center - Vaccine Study Center
    • Quebec City, Quebec, Canada
      • Unité de Recherche en Santé Publique (CHUQ),

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 61 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Written informed consent provided by the subject, who can be male or female
• Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, record safety observations and able to converse with study personnel including by personal telephone)
• Age 65 years or older at Visit 1
• Generally good health (stable chronic conditions acceptable), living independently or with minimal assistance (Clinical Frailty score 1-5) (33) and able to attend clinic appointments
• Receipt of at least one dose of TIV within the previous 2 influenza seasons, documented by written record or attested by a confident personal recollection. This refers to the trivalent seasonal vaccine, not the H1N12009 pandemic vaccine.

Exclusion Criteria:

• receipt of non-study influenza vaccine for 2011-12
• receipt of any live vaccine within 4 weeks or inactivated vaccine within one week of Visit 1 or planned administration of any non-study vaccines between Visits 1 and 2
• systemic hypersensitivity to influenza vaccine, hen's eggs or other vaccine constituent (eg neomycin sulphate, kanamycin, formalin)
• severe reaction to any previous influenza vaccine or vaccine component
• bleeding disorder, including anticoagulant therapy or thrombocytopenia, that contraindicates IM injection or blood collection (does not include daily low-dose ASA).
• incapacity to provide fully informed consent or be attentive to follow-up observations, resulting from cognitive impairment, abuse of alcohol, drug addiction
• lack of telephone access, inadequate fluency in English (or French in applicable jurisdictions), uncertain availability during the 3 week study participation period or for the 6 month follow-up visit
• immune compromise resulting from disease or immunosuppressive systemic medication use within 3 months of V1
• receipt of blood or blood product within 3 months of V1
• unstable medical condition, as indicated by a requirement for hospitalization or a substantial medication change to stabilize said condition within previous 3 months
• Clinical Frailty score of 6-7 (moderately frail or severely frail)
• history of Guillain-Barré syndrome

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Trivalent Influenza vaccine subunit; The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.	Biological: Agriflu; 0.5mL dose IM vaccination
Active Comparator: Adjuvanted Tri-valent Influenza Vaccine; The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.	Biological: Fluad; 0.5mL dose of vaccine given IM
Active Comparator: Intradermal Tri-valent Influenza vaccine; (Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.	Biological: Intanza; 0.5mL dose vaccine given IM
Active Comparator: Trivalent Split-virion Influenza vaccine; Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.	Biological: Vaxigrip; 0.5mL dose vaccine given IM

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HAI response	The primary outcome measures will be the 3-week post-vaccination immune (HAI) responses to the 3 vaccine strains present in each product, assessed by the EMEA/CHMP criteria for evaluation of immune responses to influenza vaccines in persons >60 years of age.	Day 0; Day 21; Day 180

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seroprotection rates using microneutralization titres and cytokine testing	As secondary immunologic outcomes seroprotection rates will be compared between the products using a higher titer (≥160) as threshold. Microneutralization titers will be compared among products at the 3 sampling points, using sera from 100 subjects per group. Cross-protection afforded by each vaccine against drift variants of H3N2, H1N1 and B viruses will be assessed using serum panels selected from 50 subjects in each group. Cellular immune responses elicited will be compared in subgroups of 30 subjects per vaccine in the CMI subjset.	Day 0; Day 21; and Day 70
Safety and Acceptability	Safety and acceptability of the vaccines will also be examined and compared as the safety outcomes. The primary outcome measurements will be the rates of local adverse events (pain, redness, swelling, itchiness) as rates of general adverse events are not expected to differ substantially among the products.	Days 0-6; Day 21; Day 70; and Day 180

Collaborators and Investigators

• Sponsor: University of British Columbia
• Collaborators: PHAC/CIHR Influenza Research Network
• Investigators: Principal Investigator: David W Scheifele, MD, University of Britich Columbia

Publications and helpful links

General Publications

• Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

Study record dates

Study Major Dates

• Study Start: July 1, 2011
• Primary Completion (Actual): December 1, 2011
• Study Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: June 6, 2011
• First Submitted That Met QC Criteria: June 7, 2011
• First Posted (Estimate): June 8, 2011

Study Record Updates

• Last Update Posted (Estimate): April 15, 2015
• Last Update Submitted That Met QC Criteria: April 14, 2015
• Last Verified: April 1, 2015

More Information

Terms related to this study

• Keywords: Influenza; Vaccine; Influenza vaccine; Seniors; Adjuvanted Influenza vaccine; Intradermal Influenza vaccine; Acceptability of vaccines
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human
• Other Study ID Numbers: H11-01457